Bank of New York Mellon Corp grew its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 9.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 297,176 shares of the biopharmaceutical company’s stock after purchasing an additional 25,297 shares during the period. Bank of New York Mellon Corp owned about 0.48% of TG Therapeutics worth $2,987,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of TGTX. Teachers Advisors LLC increased its stake in TG Therapeutics by 24.6% during the fourth quarter. Teachers Advisors LLC now owns 70,432 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 13,887 shares during the period. Russell Investments Group Ltd. purchased a new stake in TG Therapeutics during the first quarter worth about $811,000. Swiss National Bank increased its stake in TG Therapeutics by 18.9% during the first quarter. Swiss National Bank now owns 79,200 shares of the biopharmaceutical company’s stock worth $923,000 after purchasing an additional 12,600 shares during the period. Ameriprise Financial Inc. purchased a new stake in TG Therapeutics during the first quarter worth about $1,291,000. Finally, Parametric Portfolio Associates LLC purchased a new stake in TG Therapeutics during the first quarter worth about $928,000. Institutional investors own 49.89% of the company’s stock.
Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) opened at 11.95 on Wednesday. TG Therapeutics, Inc. has a 1-year low of $4.10 and a 1-year high of $15.35. The company’s 50 day moving average is $11.98 and its 200-day moving average is $11.34. The stock’s market capitalization is $744.60 million.
TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.01. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 154.02% and a negative net margin of 68,806.59%. Equities analysts anticipate that TG Therapeutics, Inc. will post ($1.84) earnings per share for the current fiscal year.
TGTX has been the topic of a number of recent research reports. BidaskClub lowered shares of TG Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 6th. Zacks Investment Research upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Thursday, July 13th. SunTrust Banks, Inc. restated a “buy” rating and set a $28.00 target price on shares of TG Therapeutics in a research note on Tuesday, October 3rd. Finally, FBR & Co restated a “buy” rating on shares of TG Therapeutics in a research note on Saturday, June 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $25.11.
TG Therapeutics Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
What are top analysts saying about TG Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TG Therapeutics Inc. and related companies.